New cancer drug HLX316 enters first human tests

NCT ID NCT07541534

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can shrink tumors, focusing on ovarian and related cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX316 (a protein that targets a tumor marker and helps the immune system attack cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors, especially ovarian cancer.
What could go wrong: This is a very early, small Phase I trial with only 41 people. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer metastatic malignant neoplasm neoplasm ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC SOLID TUMORS

Contacts and locations

Locations

Chongqing Cancer Hospital
NOT_YET_RECRUITING

Chongqing, China
Hubei Cancer Hospital
NOT_YET_RECRUITING

Wuhan, China
Jinan Central Clinical College of Shandong First Medical University
NOT_YET_RECRUITING

Jinan, China
Obstetris &Gynecology Hospital of Fudan University
NOT_YET_RECRUITING

Shanghai, China
Shandong Cancer Hospital
RECRUITING

Jinan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.